使用PD-1/PD-L1阻断剂的人类癌症免疫疗法。
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.
作者信息
Zheng Peilin, Zhou Zhiguang
机构信息
Institute of Metabolism and Endocrinology, The Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, National Clinical Research Center for Metabolic Diseases, Changsha, Hunan, China.
出版信息
Biomark Cancer. 2015 Sep 20;7(Suppl 2):15-8. doi: 10.4137/BIC.S29325. eCollection 2015.
Abstract
The ligation of programmed cell death-1 (PD-1) to its ligands PD-L1 and PD-L2 counteracts T-cell activation, which is critical in immune tolerance. The persistent high expression of PD-1 and PD-L1 are also observed on tumor-infiltrating lymphocytes and various tumor cells, maintaining the highly suppressive microenvironment in tumor sites and promoting tumor malignancies. The blockade of PD-1 axis with PD-L2 fusion protein or monoclonal antibodies against either PD-1 or PD-L1 has been clinically evaluated in various tumor types. This short review summarizes the progress of PD-1 axis blockade in clinical trials to evaluate its effectiveness in the antitumor immunotherapy.
摘要
程序性细胞死亡蛋白1（PD-1）与其配体PD-L1和PD-L2的结合会抵消T细胞的激活，这在免疫耐受中至关重要。在肿瘤浸润淋巴细胞和各种肿瘤细胞上也观察到PD-1和PD-L1持续高表达，维持肿瘤部位高度抑制性的微环境并促进肿瘤恶性进展。用PD-L2融合蛋白或抗PD-1或PD-L1的单克隆抗体阻断PD-1轴已在多种肿瘤类型中进行了临床评估。这篇简短的综述总结了PD-1轴阻断在临床试验中的进展，以评估其在抗肿瘤免疫治疗中的有效性。
相似文献
1
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.使用PD-1/PD-L1阻断剂的人类癌症免疫疗法。
Biomark Cancer. 2015 Sep 20;7(Suppl 2):15-8. doi: 10.4137/BIC.S29325. eCollection 2015.
2
The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.PD-1及其配体在妇科恶性肿瘤中的争议性作用
Front Oncol. 2019 Oct 15;9:1073. doi: 10.3389/fonc.2019.01073. eCollection 2019.
3
PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.PD-1 阻断细胞囊泡用于癌症免疫治疗。
Adv Mater. 2018 May;30(22):e1707112. doi: 10.1002/adma.201707112. Epub 2018 Apr 14.
4
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.PD-L2介导的免疫抑制对自发性及治疗相关抗肿瘤免疫的作用
Clin Cancer Res. 2019 Aug 1;25(15):4808-4819. doi: 10.1158/1078-0432.CCR-18-3991. Epub 2019 May 10.
5
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.基质 PD-L1 阳性调节性 T 细胞和 PD-1 阳性 CD8 阳性 T 细胞定义了不同亚组非小细胞肺癌对 PD-1/PD-L1 阻断免疫治疗的反应。
J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.
6
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.阻断树突状细胞上的程序性死亡-1配体可增强T细胞活化和细胞因子产生。
J Immunol. 2003 Feb 1;170(3):1257-66. doi: 10.4049/jimmunol.170.3.1257.
7
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.癌症治疗中的PD-1/PD-L1阻断：观点与问题
Int J Clin Oncol. 2016 Jun;21(3):462-73. doi: 10.1007/s10147-016-0959-z. Epub 2016 Feb 22.
8
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.肿瘤中 PD-L2 的表达：与癌症抗 PD-1 治疗的相关性。
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761.
9
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.PD-1/PD-L1阻断增强伊马替尼在胃肠道间质瘤中的T细胞活性和抗肿瘤疗效。
Clin Cancer Res. 2017 Jan 15;23(2):454-465. doi: 10.1158/1078-0432.CCR-16-1163. Epub 2016 Jul 28.
10
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
引用本文的文献
1
The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications.肠道菌群在肿瘤免疫治疗中的作用：最新进展及治疗意义
Heliyon. 2023 Dec 20;10(1):e23919. doi: 10.1016/j.heliyon.2023.e23919. eCollection 2024 Jan 15.
2
The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma.程序性死亡受体1（rs2227981）和程序性死亡配体1（rs2890658）基因多态性与尿路上皮细胞癌的关系
Cureus. 2023 Nov 1;15(11):e48120. doi: 10.7759/cureus.48120. eCollection 2023 Nov.
3
Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies.犬黑色素瘤：免疫疗法时代疾病诊断及疾病与免疫耐受比较机制综述
Front Vet Sci. 2023 Jan 6;9:1046636. doi: 10.3389/fvets.2022.1046636. eCollection 2022.
4
PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?程序性死亡受体配体1（PD-L1）的过表达在肺癌的不同亚型中存在差异：这会影响未来的治疗吗？
Clin Pract. 2022 Aug 24;12(5):653-671. doi: 10.3390/clinpract12050068.
5
Dysregulation of Circadian Clock Genes Associated with Tumor Immunity and Prognosis in Patients with Colon Cancer.生物钟基因失调与结肠癌患者的肿瘤免疫和预后相关。
Comput Math Methods Med. 2022 Jul 16;2022:4957996. doi: 10.1155/2022/4957996. eCollection 2022.
6
PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer.PD-1/PD-L1与宫颈癌同步放化疗的疗效相关。
Front Oncol. 2022 May 10;12:858164. doi: 10.3389/fonc.2022.858164. eCollection 2022.
7
Immune-related lncRNA pairs as novel signature to predict prognosis and immune landscape in melanoma patients.免疫相关长链非编码 RNA 对作为预测黑色素瘤患者预后和免疫图谱的新型标志物。
Medicine (Baltimore). 2022 Jan 7;101(1):e28531. doi: 10.1097/MD.0000000000028531.
8
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.PD-1/PD-L1抑制剂在慢性肝病中的新作用
Front Pharmacol. 2021 Dec 23;12:790963. doi: 10.3389/fphar.2021.790963. eCollection 2021.
9
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.癌症中新的生物学三角：肠道微生物群、免疫检查点抑制剂和抗生素。
Clin Transl Oncol. 2021 Dec;23(12):2415-2430. doi: 10.1007/s12094-021-02659-w. Epub 2021 Jun 14.
10
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures.程序性死亡配体1表达对早期切除的非小细胞肺癌预后的影响：文献的荟萃分析
Front Oncol. 2021 Feb 23;11:567978. doi: 10.3389/fonc.2021.567978. eCollection 2021.
本文引用的文献
1
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
2
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.纳武利尤单抗与伊匹木单抗联合治疗对比伊匹木单抗单药治疗未经治疗的黑色素瘤
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
3
PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.程序性死亡受体1/含Src同源2结构域蛋白酪氨酸磷酸酶2抑制肿瘤微环境中细胞毒性T细胞1/辅助性T细胞1表型反应及T细胞活化。
Cancer Res. 2015 Feb 1;75(3):508-518. doi: 10.1158/0008-5472.CAN-14-1215. Epub 2014 Dec 5.
4
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.使用针对PD-1和PD-L1通路的抗体进行人类癌症免疫治疗。
Trends Mol Med. 2015 Jan;21(1):24-33. doi: 10.1016/j.molmed.2014.10.009. Epub 2014 Oct 30.
5
Nivolumab in previously untreated melanoma without BRAF mutation.纳武利尤单抗治疗未经 BRAF 突变检测的初治黑色素瘤。
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
6
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.手术切除的非小细胞肺癌中 PD-L1 过表达与激活型 EGFR 突变的相关性。
Ann Oncol. 2014 Oct;25(10):1935-1940. doi: 10.1093/annonc/mdu242. Epub 2014 Jul 9.
7
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.程序性死亡配体1（PD-L1）的表达与人类乳腺癌的不良预后相关。
Breast Cancer Res Treat. 2014 Jul;146(1):15-24. doi: 10.1007/s10549-014-2988-5. Epub 2014 May 20.
8
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance.RGMb 是 PD-L2 的一种新型结合伴侣，其与 PD-L2 的结合促进了呼吸耐受。
J Exp Med. 2014 May 5;211(5):943-59. doi: 10.1084/jem.20130790. Epub 2014 Apr 21.
9
PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.PD-1(+)免疫细胞浸润与可手术乳腺癌患者的生存呈负相关。
Cancer Immunol Immunother. 2014 Apr;63(4):395-406. doi: 10.1007/s00262-014-1519-x. Epub 2014 Feb 11.
10
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.皮利珠单抗联合利妥昔单抗治疗滤泡性淋巴瘤复发患者的 PD1 阻断的安全性和活性：单组、开放标签、2 期试验。
Lancet Oncol. 2014 Jan;15(1):69-77. doi: 10.1016/S1470-2045(13)70551-5. Epub 2013 Dec 11.
Zotero 插件